Skip to main content

Advertisement

Table 3 Studies on prognostic significance of PIK3CA mutations in several types of cancers

From: Prognostic and clinical impact of PIK3CA mutation in gastric cancer: pyrosequencing technology and literature review

Cancer type Sample number Mutation rate (%) Mutation effect Prognosis References
Colon cancer 1212 16 Unfavorable Adjusted CS HR [31]
3.51 (1.28–9.62)
  743 14.5 Unfavorable Adjusted OS HR [25]
3.30 (1.46–7.45)
  450 18 Unfavorable Adjusted CS HR [29]
2.03 (1.15–3.57)
Rectal cancer 240 7.9 Unfavorable Adjusted RS HR [32]
3.4 (1.2–9.2)
Endometrial cancer 1063 16.2 Unfavorable Not-adjusted RS HR [33]
2.18 (1.09–4.39)
Breast cancer 687 25.3 favorable Not-adjusted CS HR [34]
0.88 (0.58–1.34)
  439 32.5 Not significant Adjusted CS HR [30]
0.7 (0.4–1.2)
  188 28.7 favorable Adjusted RS HR [35]
0.42 (0.20–0.92)
Esophageal cancer 406 7.4 Not significant Adjusted OS HR [43]
1.072 (0.79–1.44)
  219 21 favorable Adjusted OS HR [14]
0.35 (0.10–0.90)
Lung cancer 1117 3.4 Not significant OS log-lank [44]
P = 0.442
  235 3.4 Not significant OS log-lank [45]
P = 0.15
Gastric cancer 263 15.9 Not significant Adjusted OS HR [27]
1.1 (0.7–1.7)
  231 8.7 Not significant Not-adjusted OS HR [26]
1.37 (0.68–3.26)
  104 7.7 Not significant OS log-lank [28]
P = 0.96
  208 12 Not significant Not-adjusted OS HR This study
0.73 (0.58–2.57)
  1. HR hasard ratio, CS cancer specific survival, RS recurrence-free survival rate, OS overall survival rate